BR112023001007A2 - Inibidores de fatores do complemento e usos dos mesmos - Google Patents
Inibidores de fatores do complemento e usos dos mesmosInfo
- Publication number
- BR112023001007A2 BR112023001007A2 BR112023001007A BR112023001007A BR112023001007A2 BR 112023001007 A2 BR112023001007 A2 BR 112023001007A2 BR 112023001007 A BR112023001007 A BR 112023001007A BR 112023001007 A BR112023001007 A BR 112023001007A BR 112023001007 A2 BR112023001007 A2 BR 112023001007A2
- Authority
- BR
- Brazil
- Prior art keywords
- complement factor
- factor inhibitors
- disclosed
- compounds
- disease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/650905—Six-membered rings having the nitrogen atoms in the positions 1 and 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/650905—Six-membered rings having the nitrogen atoms in the positions 1 and 2
- C07F9/650947—Six-membered rings having the nitrogen atoms in the positions 1 and 2 condensed with carbocyclic rings or carbocyclic ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063054064P | 2020-07-20 | 2020-07-20 | |
| PCT/US2021/042198 WO2022020244A1 (en) | 2020-07-20 | 2021-07-19 | Inhibitors of complement factors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023001007A2 true BR112023001007A2 (pt) | 2023-03-28 |
Family
ID=79729495
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023001007A BR112023001007A2 (pt) | 2020-07-20 | 2021-07-19 | Inibidores de fatores do complemento e usos dos mesmos |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US11814404B2 (https=) |
| EP (1) | EP4185592A4 (https=) |
| JP (1) | JP7793595B2 (https=) |
| KR (1) | KR20230041758A (https=) |
| CN (2) | CN116947903A (https=) |
| AR (1) | AR123011A1 (https=) |
| AU (1) | AU2021311455A1 (https=) |
| BR (1) | BR112023001007A2 (https=) |
| CA (1) | CA3186022A1 (https=) |
| CL (1) | CL2023000191A1 (https=) |
| CO (1) | CO2023000683A2 (https=) |
| IL (1) | IL299840A (https=) |
| MX (1) | MX2023000919A (https=) |
| PE (1) | PE20231435A1 (https=) |
| PH (1) | PH12023550153A1 (https=) |
| TW (1) | TW202216168A (https=) |
| UY (1) | UY39331A (https=) |
| WO (1) | WO2022020244A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022020244A1 (en) | 2020-07-20 | 2022-01-27 | Annexon, Inc. | Inhibitors of complement factors and uses thereof |
| IL314164A (en) | 2022-01-14 | 2024-09-01 | Annexon Inc | Inhibitors of complement factors and their uses |
| AR131723A1 (es) * | 2023-01-30 | 2025-04-23 | 5Metis Inc | Compuestos que contienen boro y sus usos |
| WO2024254704A1 (en) * | 2023-06-15 | 2024-12-19 | The Governors Of The University Of Alberta | Hemiboronic heterocyclic compounds and uses thereof |
| EP4553080A1 (en) | 2023-11-07 | 2025-05-14 | Ustav Organicke Chemie a Biochemie AV CR, v.v.i. | Nucleoside derivatives as antiviral agents against coronaviruses |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5965583A (en) | 1997-04-24 | 1999-10-12 | Ortho-Mcneil Pharmaceutical, Inc. | Substituted imidazoles useful in the treatment of inflammatory disease |
| EP1971664B1 (en) * | 2006-01-13 | 2015-09-09 | LG Chem, Ltd. | Emitting materials and organic light emitting device using the same |
| KR20100031723A (ko) | 2007-07-07 | 2010-03-24 | 이데미쓰 고산 가부시키가이샤 | 크리센 유도체 및 이를 이용한 유기 전계 발광 소자 |
| KR101233377B1 (ko) | 2008-12-30 | 2013-02-18 | 제일모직주식회사 | 신규한 유기광전소자용 화합물 및 이를 포함하는 유기광전소자 |
| WO2013049332A1 (en) * | 2011-09-29 | 2013-04-04 | Infinity Pharmaceuticals, Inc. | Inhibitors of monoacylglycerol lipase and methods of their use |
| WO2015003146A1 (en) * | 2013-07-03 | 2015-01-08 | Georgetown University | Boronic acid derivatives of resveratrol for activating deacetylase enzymes |
| DK3019240T3 (da) | 2013-07-09 | 2024-06-03 | Annexon Inc | Anti-komplementfaktor C1Q antistoffer og anvendelser deraf |
| TWI532741B (zh) | 2013-09-04 | 2016-05-11 | 喜星素材股份有限公司 | 含吡唑之多環化合物及使用其之有機發光裝置 |
| KR101635154B1 (ko) | 2014-08-28 | 2016-06-30 | (주)더블유에스 | 피리딜기가 결합된 트리아진 유도체 및 이를 포함한 유기 전계발광 소자 |
| KR102233296B1 (ko) * | 2014-11-18 | 2021-03-29 | 덕산네오룩스 주식회사 | 유기전기 소자용 화합물, 이를 이용한 유기전기소자 및 그 전자 장치 |
| AR103397A1 (es) * | 2015-01-13 | 2017-05-10 | Syngenta Participations Ag | Oxoborazoles microbicidas |
| US10111885B2 (en) * | 2015-03-13 | 2018-10-30 | Resverlogix Corp. | Compositions and therapeutic methods for the treatment of complement-associated diseases |
| KR101981245B1 (ko) | 2015-10-27 | 2019-05-22 | 주식회사 엘지화학 | 고리 화합물 및 이를 포함하는 유기 발광 소자 |
| KR101806464B1 (ko) | 2015-11-19 | 2017-12-07 | (주)랩토 | 피리딜기가 결합된 피리미딘 유도체 및 이를 이용한 유기 전계 발광 소자 |
| KR102496411B1 (ko) | 2016-01-06 | 2023-02-06 | 덕산네오룩스 주식회사 | 유기전기 소자용 화합물, 이를 이용한 유기전기소자 및 그 전자 장치 |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| WO2019240471A1 (ko) | 2018-06-11 | 2019-12-19 | 주식회사 엘지화학 | 헤테로고리 화합물 및 이를 포함하는 유기 발광 소자 |
| WO2020032428A1 (ko) * | 2018-08-09 | 2020-02-13 | 덕산네오룩스 주식회사 | 유기전기 소자용 화합물을 포함하는 유기전기소자 및 그 전자 장치 |
| CN109574917B (zh) | 2018-12-03 | 2020-12-08 | 武汉尚赛光电科技有限公司 | 一种芴酮衍生物及其制备和应用 |
| CN109574910B (zh) * | 2018-12-19 | 2021-07-02 | 山西大学 | 一种咔唑衍生物mcab及其制备方法和应用 |
| CN111087387B (zh) | 2019-12-26 | 2022-04-29 | 厦门天马微电子有限公司 | 一种有机化合物、显示面板及显示装置 |
| CN111423390A (zh) | 2020-03-30 | 2020-07-17 | 北京燕化集联光电技术有限公司 | 一种新型结构化合物及其应用 |
| CN111662309B (zh) | 2020-07-10 | 2021-11-09 | 北京燕化集联光电技术有限公司 | 一种多杂环结构化合物及其应用 |
| WO2022020244A1 (en) | 2020-07-20 | 2022-01-27 | Annexon, Inc. | Inhibitors of complement factors and uses thereof |
| CN113045585A (zh) | 2021-03-16 | 2021-06-29 | 吉林奥来德光电材料股份有限公司 | 一种有机稠环化合物及其制备方法和应用 |
| CN113831332B (zh) | 2021-10-29 | 2024-06-18 | 长春海谱润斯科技股份有限公司 | 一种含氮杂环衍生物及其在有机电致发光器件中的应用 |
| IL314164A (en) | 2022-01-14 | 2024-09-01 | Annexon Inc | Inhibitors of complement factors and their uses |
-
2021
- 2021-07-19 WO PCT/US2021/042198 patent/WO2022020244A1/en not_active Ceased
- 2021-07-19 CN CN202310870524.5A patent/CN116947903A/zh active Pending
- 2021-07-19 EP EP21845924.6A patent/EP4185592A4/en active Pending
- 2021-07-19 AU AU2021311455A patent/AU2021311455A1/en active Pending
- 2021-07-19 KR KR1020237005805A patent/KR20230041758A/ko active Pending
- 2021-07-19 PE PE2023000109A patent/PE20231435A1/es unknown
- 2021-07-19 JP JP2023503413A patent/JP7793595B2/ja active Active
- 2021-07-19 CN CN202180059041.6A patent/CN116261564A/zh active Pending
- 2021-07-19 AR ARP210102028A patent/AR123011A1/es unknown
- 2021-07-19 IL IL299840A patent/IL299840A/en unknown
- 2021-07-19 CA CA3186022A patent/CA3186022A1/en active Pending
- 2021-07-19 MX MX2023000919A patent/MX2023000919A/es unknown
- 2021-07-19 US US17/379,334 patent/US11814404B2/en active Active
- 2021-07-19 PH PH1/2023/550153A patent/PH12023550153A1/en unknown
- 2021-07-19 BR BR112023001007A patent/BR112023001007A2/pt unknown
- 2021-07-20 UY UY0001039331A patent/UY39331A/es unknown
- 2021-07-20 TW TW110126637A patent/TW202216168A/zh unknown
-
2023
- 2023-01-19 CL CL2023000191A patent/CL2023000191A1/es unknown
- 2023-01-20 CO CONC2023/0000683A patent/CO2023000683A2/es unknown
- 2023-10-04 US US18/376,526 patent/US12509474B2/en active Active
-
2025
- 2025-11-20 US US19/395,200 patent/US20260070932A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CL2023000191A1 (es) | 2023-09-08 |
| US20240109920A1 (en) | 2024-04-04 |
| UY39331A (es) | 2022-02-25 |
| AU2021311455A1 (en) | 2023-02-16 |
| CN116947903A (zh) | 2023-10-27 |
| MX2023000919A (es) | 2023-04-19 |
| CA3186022A1 (en) | 2022-01-27 |
| IL299840A (en) | 2023-03-01 |
| PE20231435A1 (es) | 2023-09-14 |
| US11814404B2 (en) | 2023-11-14 |
| EP4185592A1 (en) | 2023-05-31 |
| CO2023000683A2 (es) | 2023-01-26 |
| AR123011A1 (es) | 2022-10-19 |
| EP4185592A4 (en) | 2024-08-21 |
| US12509474B2 (en) | 2025-12-30 |
| JP7793595B2 (ja) | 2026-01-05 |
| JP2023534974A (ja) | 2023-08-15 |
| KR20230041758A (ko) | 2023-03-24 |
| US20220048930A1 (en) | 2022-02-17 |
| PH12023550153A1 (en) | 2024-03-18 |
| WO2022020244A1 (en) | 2022-01-27 |
| US20260070932A1 (en) | 2026-03-12 |
| TW202216168A (zh) | 2022-05-01 |
| CN116261564A (zh) | 2023-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023001007A2 (pt) | Inibidores de fatores do complemento e usos dos mesmos | |
| BR112021023359A2 (pt) | Inibidores de g12c de kras e usos dos mesmos | |
| CY1125784T1 (el) | Υποκατεστημενες δικυκλικες ετεροκυκλικες ενωσεις ως αναστολεις της prmt5 | |
| BR112021020285A2 (pt) | Métodos e composições para degradação de proteína alvejada | |
| CY1125169T1 (el) | ΕΝΩΣΕΙΣ ΑΜΙΝΟΠΥΡΑΖΙΝΟ ΔΙΟΛΗΣ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΡΙ3Κ-γ | |
| BR112021010715A2 (pt) | Pirazolopirimidinas substituídas e purinas substituídas e seu uso como inibidores de protease de processamento ubiquitina-específica 1 (usp1) | |
| BR112022016382A2 (pt) | Triptaminas específicas para o uso no tratamento de doenças do humor | |
| BR112018015273A2 (pt) | derivados de benzimidazol como moduladores de ror-gama | |
| CY1122046T1 (el) | Δικυκλικα ετεροκυκλικα παραγωγα ως αναστολεις βρομοτομεων | |
| BR112021017772A2 (pt) | Bloqueadores de canais de íons carregados e métodos para uso | |
| EA201890307A1 (ru) | Индазольные и азаиндазольные соединения как ингибиторы irak-4 | |
| EA201892207A1 (ru) | Индолкарбоксамидные соединения | |
| EA201890308A1 (ru) | Замещенные азасоединения как ингибиторы irak-4 | |
| CY1125488T1 (el) | Παραγωγα πυριδινης και θεραπευτικες χρησεις αυτων ως αναστολεις trpc6 | |
| CY1122587T1 (el) | 1-[2-(αμινομεθυλο)βενζυλο]-2-θειοξο-1,2,3,5-τετραϋδρο-4η-πυρρολο[3,2-d]πυριμιδιν-4-ονες ως αναστολεις της μυελοϋπεροξειδασης | |
| MX2024015576A (es) | Tratamiento para migra?as | |
| EA201892075A1 (ru) | Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей | |
| JOP20200086B1 (ar) | مشتقات إيميدازول مكثفة بها استبدال بمجموعات هيدروكسي ثلاثية كمثبطات لـ pi3k-جاما | |
| CY1124773T1 (el) | Τοπικη φαρμακευτικη συνθεση η οποια εμπεριεχει τουλαχιστον αμιτριπτυλινη για τη θεραπευτικη αντιμετωπιση του περιφερικου νευροπαθητικου αλγους | |
| BR112021021826A2 (pt) | Terapias de combinação compreendendo os inibidores de apremilast e tyk2 | |
| BR112022012278A2 (pt) | Combinações | |
| BR112016029067A2 (pt) | ?composto, composição farmacêutica, e, métodos para inibir o canal de potássio medular externo renal, para causar diurese, natriurese ou ambas e para tratar um ou mais distúrbios? | |
| DK4185318T3 (da) | Forlængede, højdosis-VEGF-antagonistregimer til behandling af angiogene øjensygdomme | |
| CY1123576T1 (el) | Συμπυκνωμενα παραγωγα θειοφαινιου χρησιμα ως αναστολεις του napi-iib | |
| EA202192746A1 (ru) | Гетероциклические соединения и их применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |